RefleXion Medical will install its X1 platform with SCINTIX biology-guided radiotherapy at Beverly Hills Cancer Center, making it the first freestanding cancer center to adopt the technology.
SCINTIX therapy uses biological signals from a patient’s tumor to guide radiation treatment in real time. It is currently indicated for FDG-guided treatment of lung and bone tumors and is under investigation for additional cancer types.
Unlike conventional radiotherapy, which relies on static imaging, SCINTIX detects emissions from a PET tracer consumed by cancer cells to dynamically adjust radiation delivery. This approach allows for precise targeting of tumors while minimizing exposure to surrounding healthy tissue.
“At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments,” said Dr. Arash (Ari) Gabayan, chief of radiation oncology and imaging at BHCC. “We are excited to be among the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient’s tumor to precisely direct the radiation beam to its tumor target.”
Starting in 2025, CMS will introduce new reimbursement codes for SCINTIX therapy at freestanding cancer centers, as well as professional reimbursement for physicians in both freestanding and hospital outpatient settings.
“We are thrilled to count BHCC and its world-class cancer physicians among our early customers, and as our first freestanding cancer center," said RefleXion CEO, Todd Powell. "Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable.”
BHCC worked with Select Healthcare Solutions, a provider of medical technology solutions for independent physician groups, to integrate SCINTIX therapy into its treatment offerings.
